dismiss

Clean Sweep Live Auction on Wed. February 27th. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Rad Oncology Homepage

Canon adds radiation oncology functioning to Aquilion CTs Can be shared between radiology and radiation oncology departments

Philips and MIM Software collab to streamline radiotherapy treatment planning Integrate portfolios of CT, MR and software solutions

ZAP Surgical launches radiosurgery platform for treating brain tumors Lowers cost of SRS with self-shielding technology

First Southeast Asian proton therapy center opens in India Will treat more than 3 million Indians with cancer, and other SE Asian populations

FDA clears MIM SurePlan molecular radiotherapy software Can measure the absorbed dose from MRT for individual patients

Addressing the radiation-related cancer risk of obese patients A complex problem and a call for better dose optimization

Mevion to install PT system at Mercy Hospital St. Louis Equipped with HYPERSCAN technology

GE and VUMC partner to make cancer immunotherapy safer and more precise Five-year collab will yield new AI apps and PET tracers

Proton therapy pioneer James M. Slater dies at 89 Oversaw creation of the world's first proton treatment center

UK and US researchers develop AI models for evaluating emotional burden of cancer More clearly assesses reduction in quality of life

Radiotherapy does not benefit end-stage lung cancer patients

by John W. Mitchell , Senior Correspondent
A widespread protocol for end-stage, non-small cell lung cancer patients whose disease has metastasized into their brain does not improve survival according to just-published findings in the British medical journal The Lancet.

"Before the QUARTZ trail, there was no evidence that whole brain radiotherapy enhanced our non-small cell lung cancer patients' quality of life or overall survival," Dr. Paula Mulvenna, Consultant Clinical Oncologist, Newcastle Hospitals NHS Foundation Trust, U.K. told HCB News.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



The Quality of Life after Treatment for Brain Metastases (QUARTZ) trial included 538 patients from 69 health centers in the U.K. and three in Australia between March, 2007 and August, 2014. The patients were randomly assigned to two different protocol groups, with one group receiving radiotherapy as part of their care.

The data demonstrated that patients in both groups lived about 65 days and experienced a similar quality of life.

"The QUARTZ trial results confirmed that whole brain radiotherapy can be safely omitted without a clinically significant reduction in overall survival or quality of life. This means some patients can be spared the potential side effects of whole brain radiotherapy," said Mulvenna. Such side effects can include headaches, nausea, vomiting, fatigue, hearing loss, and memory and speech difficulty.

Mulvenna added that for patients under 60, radiotherapy may offer another three weeks of survival, but the treatment should still be weighed against the potential side effects. She also said that the study is widely accepted in the oncology sector.

"Colleagues have welcomed this data which has given them better evidence for informed conversations with patients regarding the best approach to quality and duration of life," said Mulvenna. "The uptake of whole brain radiotherapy as standard treatment has fallen significantly in the UK since our results have become public."

According to the American Cancer Society, lung cancer (both small and non-small cell) is the second most common cancer in men and women. While research has doubled overall cancer survival rates, progress has not been the same across all cancer types and survival for lung cancer remains low. In the U.S. about 225,000 new cases are diagnosed annually, with about 158,000 deaths annually.

She added that the QUARTZ study indicates that steroids and supportive care - including pain killers - are the best therapy for such lung to brain cancer patients.

Rad Oncology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED